A randomized phase II study of degarelix combined with anti-androgen for prostate cancer

A randomized phase II study of degarelix combined with anti-androgen for prostate cancer - Degarelix with anti-androgen for prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011506

Enrollment

Registered

2013-08-17

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Degarelix Degarelix + bicalutamide

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Histologically proven prostate adenocarcinoma. Patients indicated for androgen deprivation therapy.

Exclusion criteria

Exclusion criteria: Previous or present endocrine therapy for prostate cancer.

Design outcomes

Primary

Measure	Time frame
Changes in serum level of prostate specific antigen at Day 28.	—

Countries

Japan

Contacts

Public ContactMasahiro Nozawa

Kinki University Faculry of Medicine Urology

nozawa06@med.kindai.ac.jp0723660221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026